NCT06973811View on ClinicalTrials.gov

ZR-MTX for PIOL Phase II Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 10, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2029

Conditions
Primary Intraocular Lymphoma
Interventions
DRUG

Methotrexate

400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses

DRUG

Rituximab (R)

Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol

DRUG

Zanubrutinib

160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase

DRUG

Methotrexate (MTX)

Methotrexate 3.5g/m2 intravenous infusion d1, every 21 days for cycle 5 and 6 only.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER